GSK’s entry into Oncology with the launch of specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) was well-received by healthcare professionals. Shares of GlaxoSmithKline Pharmaceuticals Ltd ended at ₹2,599.75, down by ₹61.75, or 2.32%, on the BSE.
